103 related articles for article (PubMed ID: 38750874)
1. Individualized dosing of follitropin delta affects live birth and safety in in vitro fertilization treatment: an individual participant data meta-analysis of randomized controlled trials.
Nelson SM; Shaw M; Alrashid K; Anderson RA
Fertil Steril; 2024 May; ():. PubMed ID: 38750874
[TBL] [Abstract][Full Text] [Related]
2. BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle.
Lobo R; Soerdal T; Ekerhovd E; Cohlen B; Porcu E; Schenk M; Shufaro Y; Smeenk J; Suerdieck MB; Pinton P; Pinborg A;
Hum Reprod; 2024 May; ():. PubMed ID: 38723189
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
[TBL] [Abstract][Full Text] [Related]
4. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
[TBL] [Abstract][Full Text] [Related]
5. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
Yang R; Zhang Y; Liang X; Song X; Wei Z; Liu J; Yang Y; Tan J; Zhang Q; Sun Y; Wang W; Qian W; Jin L; Wang S; Xu Y; Yang J; Goethberg M; Mannaerts B; Wu W; Zheng Z; Qiao J
Reprod Biol Endocrinol; 2022 Oct; 20(1):147. PubMed ID: 36195924
[TBL] [Abstract][Full Text] [Related]
6. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial.
Ishihara O; Arce JC;
Reprod Biomed Online; 2021 May; 42(5):909-918. PubMed ID: 33722477
[TBL] [Abstract][Full Text] [Related]
7. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
[TBL] [Abstract][Full Text] [Related]
8. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
Ngwenya O; Lensen SF; Vail A; Mol BWJ; Broekmans FJ; Wilkinson J
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD012693. PubMed ID: 38174816
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.
Palomba S; Caserta D; Levi-Setti PE; Busnelli A
J Ovarian Res; 2024 Mar; 17(1):60. PubMed ID: 38486276
[TBL] [Abstract][Full Text] [Related]
11. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.
Fernández-Sánchez M; Visnova H; Yuzpe A; Klein BM; Mannaerts B; Arce JC;
Reprod Biomed Online; 2019 Apr; 38(4):528-537. PubMed ID: 30713022
[TBL] [Abstract][Full Text] [Related]
12. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight.
Višnová H; Papaleo E; Martin FS; Koziol K; Klein BM; Mannaerts B
Reprod Biomed Online; 2021 Dec; 43(6):1019-1026. PubMed ID: 34756645
[TBL] [Abstract][Full Text] [Related]
14. Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol.
Sánchez MF; Larsson P; Serrano MF; Bosch E; Velasco JAG; López ES; Mannaerts B
Reprod Biol Endocrinol; 2023 May; 21(1):45. PubMed ID: 37194068
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.
Ishihara O; Klein BM; Arce JC;
Fertil Steril; 2021 Jun; 115(6):1478-1486. PubMed ID: 33272623
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
18. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin.
Bissonnette F; Minano Masip J; Kadoch IJ; Librach C; Sampalis J; Yuzpe A
Fertil Steril; 2021 Apr; 115(4):991-1000. PubMed ID: 33267959
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of follitropin delta versus follitropin alpha/beta in infertility treatment: A systematic review and meta-analysis.
Komiya S; Watanabe J; Terayama T; Kamijo K; Okada H
Reprod Med Biol; 2024; 23(1):e12573. PubMed ID: 38528991
[TBL] [Abstract][Full Text] [Related]
20. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
